Logo

Merck Collaborates with Amathus Therapeutics to Develop Treatments for Neurodegenerative Diseases

Share this

Merck Collaborates with Amathus Therapeutics to Develop Treatments for Neurodegenerative Diseases

Shots:

  • Amathus to receive upfront and will be eligible for ~$500M milestones/program- if Merck exercise its option and will be responsible for identifying & progressing novel chaperone activators through preclinical discovery
  • Merck to get an option to acquire Amathus Therapeutics along with its pipeline of mitochondrial targeted candidate to treat neurodegenerative disorders and renal diseases
  • Following the exercise of the option- Merck will lead the clinical development and commercialization of therapies for neurodegenerative diseases

 ­ Ref: Businesswire | Image: Merck 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions